Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 38Head & Neck 1

Conditions

Head and Neck Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Nasopharyngeal Carcinoma 22Mouth Neoplasms 10Oropharyngeal Neoplasms 8Carcinoma, Squamous Cell 8Laryngeal Neoplasms 7Neoplasms 6Melanoma 5Lung Neoplasms 5Colorectal Neoplasms 5Pharyngeal Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Kidney Neoplasms 4Breast Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Tongue Neoplasms 2Thyroid Neoplasms 2Skin Neoplasms 2Recurrence 2Paranasal Sinus Neoplasms 2Nasopharyngeal Neoplasms 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Laryngeal Diseases 2Hypopharyngeal Neoplasms 2Glioblastoma 2

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Cisplatin 3spartalizumab 2regorafenib 2durvalumab 2Paclitaxel 2Itraconazole 2Immune Checkpoint Inhibitors 2Gemcitabine 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1ribociclib 1osimertinib 1obinutuzumab 1nazartinib 1naptumomab estafenatox 1liposomal doxorubicin 1enzalutamide 1elgemtumab 1aflibercept 1abiraterone 1SGN-LIV1A 1Ritonavir 1Remote Patient Monitoring 1Oxaliplatin 1ON 01910 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Drug Therapy × Head & Neck × Clear all
NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Merus B.V.

Phase 1/2 Active not recruiting
194 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡